Repurposing Old Drugs into New Epigenetic Inhibitors: Promising Candidates for Cancer Treatment?
authors Moreira-Silva, F; Camilo, V; Gaspar, V; Mano, JE; Henrique, R; Jeronimo, C
nationality International
journal PHARMACEUTICS
author keywords cancer; prostate cancer; CRPC; drug repurposing; epigenetic; epi-drugs
keywords HISTONE DEACETYLASE INHIBITOR; TUMOR-SUPPRESSOR GENES; PROSTATE-CANCER; DNA METHYLATION; MYELODYSPLASTIC SYNDROMES; TRICHOSTATIN-A; DEMETHYLASE 1; CELL-DEATH; EXPRESSION; APICIDIN
abstract Epigenetic alterations, as a cancer hallmark, are associated with cancer initiation, progression and aggressiveness. Considering, however, that these alterations are reversible, drugs that target epigenetic machinery may have an inhibitory effect upon cancer treatment. The traditional drug discovery pathway is time-consuming and expensive, and thus, new and more effective strategies are required. Drug Repurposing (DR) comprises the discovery of a new medical indication for a drug that is approved for another indication, which has been recalled, that was not accepted or failed to prove efficacy. DR presents several advantages, mainly reduced resources, absence of the initial target discovery process and the reduced time necessary for the drug to be commercially available. There are numerous old drugs that are under study as repurposed epigenetic inhibitors which have demonstrated promising results in in vitro tumor models. Herein, we summarize the DR process and explore several repurposed drugs with different epigenetic targets that constitute promising candidates for cancer treatment, highlighting their mechanisms of action.
publisher MDPI
year published 2020
volume 12
issue 5
digital object identifier (doi) 10.3390/pharmaceutics12050410
web of science category Pharmacology & Pharmacy
subject category Pharmacology & Pharmacy
unique article identifier WOS:000543393700006
  ciceco authors
  impact metrics
journal analysis (jcr 2019):
journal impact factor 4.421
5 year journal impact factor Not Available
category normalized journal impact factor percentile 83.889
dimensions (citation analysis):
altmetrics (social interaction):



 


Apoio

1suponsers_list_ciceco.jpg